-
Mashup Score: 56
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Mosunetuzumab is a CD20xCD3 T-cell–engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator assessment, after an overall median follow-up of 3.5 years in patients with relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphoma (iNHL/aNHL) from the dose-escalation stage of a phase I/II study of mosunetuzumab (ClinicalTrials.gov identifier: NCT02500407). Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions - 6 day(s) ago
Key Points. In relapsed MCL, venetoclax-ibrutinib achieves 7-year PFS of 30%, TTF of 39%, OS of 43% and durable remissions in 10/17 respondersElective trea
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 120Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma - 6 day(s) ago
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targ
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials - 11 day(s) ago
Key Points. Acalabrutinib-based regimens achieve long-term efficacy in patients with higher-risk CLL, across all lines of therapySafety profile of acalabru
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib - 13 day(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies - 16 day(s) ago
Key Points. The CLL-IPI retains prognostic value for PFS, but its impact appears diminished in predicting survival with targeted drugs.Improved survival wi
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 99B-cell non-Hodgkin lymphomas - 19 day(s) ago
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkin lymphomas was last reviewed in The Lancet in 2017, a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 97B-cell non-Hodgkin lymphomas - 20 day(s) ago
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkin lymphomas was last reviewed in The Lancet in 2017, a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 97B-cell non-Hodgkin lymphomas - 20 day(s) ago
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkin lymphomas was last reviewed in The Lancet in 2017, a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL - 20 day(s) ago
Key Points. Versus zanubrutinib, acalabrutinib plus obinutuzumab had longer INV-PFS whereas acalabrutinib monotherapy showed no difference.The odds of havi
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study | Journal of Clinical Oncology https://t.co/4CwmowDTTK